The lessons learned from PARP inhibitors have demonstrated that the challenges in managing toxicities resulted from combination therapies, yet clinicians should focus on both monotherapy and combination therapy to establish the finest therapeutic option for cancer patients. The gene discussed is PARP1; the disease is cancer.